FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to field of pharmaceutics and medicine and deals with pharmaceutical composition or therapeutic combination for treatment of vascular pathological states, diabetes, obesity and reduction of concentration of sterols in plasma, which include: (a) at least, one activator of peroxisome proliferator-activated receptor, selected from group, consisting of fenofibrate, clofibrate, gemfibrozil, cyprofibrate, bezafibrate, clinofibrate, binifibrate, lifibrole or their mixture, and (b) sterol absorption inhibitor, represented by formula
, or its pharmaceutically acceptable salt.
EFFECT: claimed are combinations of activator (activators) of peroxisome proliferator-activated receptor (ppar), and inhibitor (inhibitors) of sterol absorption and treatment of vascular diseases.
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF SUBSTITUTED AZETIDINONES FOR TREATMENT OF SYTOSTEROLEMIA | 2002 |
|
RU2756946C2 |
| SUGAR RESIDUE-SUBSTITUTED 2-AZETHIDINONES USEFUL FOR USING AS HYPOCHOLESTEROLEMIC PREPARATIONS | 2001 |
|
RU2297422C2 |
| COMBINATION OF IAP AND FLT3 INHIBITORS | 2007 |
|
RU2456983C2 |
| PIPERIDINYLPIPERAZINE DERIVATIVES APPLICABLE AS CHEMOKINE RECEPTOR INHIBITORS | 2006 |
|
RU2411241C2 |
| COMBINATIONS WHICH INCLUDE RECEPTOR S1P AGONIST AND JAK3 KINASE INHIBITOR | 2005 |
|
RU2415678C2 |
| COMBINED THERAPY INCLUDING SGLT INHIBITORS AND DPP4 INHIBITORS | 2009 |
|
RU2481106C2 |
| INHIBITORS OF FACTOR VIIA | 2000 |
|
RU2248359C2 |
| NEW INHIBITORS OF 17 β-HYDROXYSTEROID-DEHYDROGENASE TYPE I | 2004 |
|
RU2369614C2 |
| COMBINATED INHIBITORS OF FBP-ASE AND ANTIDIABETIC AGENTS FOR DIABETES TREATMENT | 2001 |
|
RU2328308C2 |
| CONJUGATES OF BINDER (ADC) WITH KSP INHIBITORS | 2014 |
|
RU2698697C2 |
